ALCAM and pancreatic neoplasm: Our flow cytometric analyses of resected pancreatic cancer tissues revealed that the percentage of CD166+ cells ranged from 33.8 to 70.2% among EpCAM+ cells, suggesting that CD166 expression was frequent in pancreatic cancers.